CDXS
Price
$1.64
Change
-$0.05 (-2.98%)
Updated
Dec 26, 02:27 PM (EDT)
Capitalization
151.74M
62 days until earnings call
Intraday BUY SELL Signals
LCTX
Price
$1.65
Change
-$0.04 (-2.38%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
386.95M
69 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CDXS vs LCTX

Header iconCDXS vs LCTX Comparison
Open Charts CDXS vs LCTXBanner chart's image
Codexis
Price$1.64
Change-$0.05 (-2.98%)
Volume$300
Capitalization151.74M
Lineage Cell Therapeutics
Price$1.65
Change-$0.04 (-2.38%)
Volume$3.3K
Capitalization386.95M
CDXS vs LCTX Comparison Chart in %
CDXS
Daily Signal:
Gain/Loss:
LCTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CDXS vs. LCTX commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and LCTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (CDXS: $1.68 vs. LCTX: $1.68)
Brand notoriety: CDXS and LCTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 23% vs. LCTX: 17%
Market capitalization -- CDXS: $151.74M vs. LCTX: $386.95M
CDXS [@Biotechnology] is valued at $151.74M. LCTX’s [@Biotechnology] market capitalization is $386.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 1 FA rating(s) are green whileLCTX’s FA Score has 0 green FA rating(s).

  • CDXS’s FA Score: 1 green, 4 red.
  • LCTX’s FA Score: 0 green, 5 red.
According to our system of comparison, LCTX is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while LCTX’s TA Score has 2 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 4 bearish.
  • LCTX’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, CDXS is a better buy in the short-term than LCTX.

Price Growth

CDXS (@Biotechnology) experienced а +4.35% price change this week, while LCTX (@Biotechnology) price change was -5.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.37%. For the same industry, the average monthly price growth was +0.28%, and the average quarterly price growth was +55.43%.

Reported Earning Dates

CDXS is expected to report earnings on Feb 26, 2026.

LCTX is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+0.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LCTX($387M) has a higher market cap than CDXS($152M). LCTX YTD gains are higher at: 234.328 vs. CDXS (-64.780). LCTX has higher annual earnings (EBITDA): -19.68M vs. CDXS (-55.32M). CDXS has more cash in the bank: 58.7M vs. LCTX (40.5M). LCTX has less debt than CDXS: LCTX (2.62M) vs CDXS (68.6M). CDXS has higher revenues than LCTX: CDXS (52.9M) vs LCTX (10.8M).
CDXSLCTXCDXS / LCTX
Capitalization152M387M39%
EBITDA-55.32M-19.68M281%
Gain YTD-64.780234.328-28%
P/E RatioN/AN/A-
Revenue52.9M10.8M490%
Total Cash58.7M40.5M145%
Total Debt68.6M2.62M2,617%
FUNDAMENTALS RATINGS
CDXS vs LCTX: Fundamental Ratings
CDXS
LCTX
OUTLOOK RATING
1..100
3261
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10090
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
6537
P/E GROWTH RATING
1..100
10058
SEASONALITY SCORE
1..100
503

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (31) in the Chemicals Specialty industry is somewhat better than the same rating for LCTX (65) in the null industry. This means that CDXS’s stock grew somewhat faster than LCTX’s over the last 12 months.

LCTX's Profit vs Risk Rating (90) in the null industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that LCTX’s stock grew similarly to CDXS’s over the last 12 months.

LCTX's SMR Rating (99) in the null industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that LCTX’s stock grew similarly to CDXS’s over the last 12 months.

LCTX's Price Growth Rating (37) in the null industry is in the same range as CDXS (65) in the Chemicals Specialty industry. This means that LCTX’s stock grew similarly to CDXS’s over the last 12 months.

LCTX's P/E Growth Rating (58) in the null industry is somewhat better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that LCTX’s stock grew somewhat faster than CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSLCTX
RSI
ODDS (%)
Bullish Trend 3 days ago
71%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 23 days ago
77%
Declines
ODDS (%)
Bearish Trend 12 days ago
86%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signal:
Gain/Loss:
LCTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HAIIF2.80N/A
N/A
Haitian International Holdings Ltd
WOLWF19.27N/A
N/A
Woolworths Group Limited
XFABF5.85N/A
N/A
X-FAB SILICON FOUNDRIES SE
DCMDF1.22N/A
N/A
Data Communications Management Corp.
CCMCF0.39N/A
N/A
Core Critical Metals Corp.

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+1.82%
DNLI - CDXS
51%
Loosely correlated
+1.07%
ABCL - CDXS
50%
Loosely correlated
+0.81%
BEAM - CDXS
50%
Loosely correlated
+1.33%
NTLA - CDXS
50%
Loosely correlated
+1.80%
ABSI - CDXS
49%
Loosely correlated
+1.14%
More

LCTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
+1.20%
MDGL - LCTX
43%
Loosely correlated
+0.10%
ABCL - LCTX
39%
Loosely correlated
+0.81%
CDXS - LCTX
37%
Loosely correlated
+1.82%
DSGN - LCTX
35%
Loosely correlated
+1.46%
CRSP - LCTX
35%
Loosely correlated
+0.44%
More